In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of research and development by streamlining the path from concept to clinical trials and, ultimately, to market. The article delves into the intricacies of implementing a fast-to-clinic/market strategy, underlining the empowering role of strategic decision-making in preclinical and commercial stages. The plan advocates for a phase-appropriate approach, where the development decision is tailored to each phase of the product’s lifecycle. This ensures that resources are allocated efficiently, risks are managed effectively, and the product can move through the development pipeline accelerated without compromising quality or regulatory compliance. The article also discusses the role of CDMOs in facilitating rapid product development and the essential factors biotech companies must consider when selecting a partner for outsourcing. These factors include the CDMO’s expertise in navigating regulatory landscapes, technological capabilities, and ability to scale processes efficiently. Moreover, the article stresses the importance of agility and flexibility in the fast-to-clinic/market approach. Biotech companies are encouraged to adopt adaptable strategies that respond to the fast-evolving regulatory and market landscapes.
References
[1]
(2023) Navigating the Small Molecule CMC Pathway: Strategies for Avoiding Regulatory Hurdles and Early Drug Development Pitfalls. https://xtalks.com/webinars/navigating-the-small-molecule-cmc-pathway-strategies-for-avoiding-regulatory-hurdles-and-early-drug-development-pitfalls/
[2]
Sutherland, J.J., Woodhead, J.L. and Longo, J. (2021) Exploring Different Approaches to Improve the Success of Drug Discovery and Development Projects. Future Journal of Pharmaceutical Sciences, 7, 25.
[3]
(2023) Phase-Appropriate CMC Activities Facilitate the Transition from Early Development through Commercialization. https://www.pharmasalmanac.com
[4]
Castellanos, M.M., Gressard, H., Li, X., Magagnoli, C., Moriconi, A., Stranges, D., et al. (2023) CMC Strategies and Advanced Technologies for Vaccine Development to Boost Acceleration and Pandemic Preparedness. Vaccines, 11, Article 1153. https://doi.org/10.3390/vaccines11071153
[5]
McKinsey & Company (2023) Preclinical Development of New Medicines. https://www.mckinsey.com
[6]
ICON (2023) CMC in Drug Development and Life Cycle Management. https://www.iconplc.com
[7]
Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P.G. and Rabosio, E. (2020) The Endless Frontier? The Recent Increase of R & D Productivity in Pharmaceuticals. Journal of Translational Medicine, 18, Article No. 162. https://doi.org/10.1186/s12967-020-02313-z
[8]
Michaeli, D.T., Michaeli, T., Albers, S., Boch, T. and Michaeli, J.C. (2023) Special FDA Designations for Drug Development: Orphan, Fast Track, Accelerated Approval, Priority Review, and Breakthrough Therapy. The European Journal of Health Economics. https://doi.org/10.1007/s10198-023-01639-x
[9]
U.S. Food and Drug Administration (FDA) (2023) Understanding Investigational Drugs for Patients. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
[10]
Steinmetz, K.L. and Spack, E.G. (2009) The Basics of Preclinical Drug Development for Neurodegenerative Disease Indications. BMC Neurology, 9, S2. https://bmcneurol.biomedcentral.com
[11]
U.S. Food and Drug Administration (2020) Investigational New Drug (IND) Application. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
[12]
U.S. Food and Drug Administration (2023) Overview of FDA expedited Programs for Serious Conditions. https://www.fda.gov/media/94063/download
[13]
Marks, P. and Gottlieb, S. (2018) Balancing Safety and Innovation for Cell-Based Regenerative Medicine. The New England Journal of Medicine, 378, 954-959.
[14]
PowerPak (2023) The FDA Accelerated Drug Approval Process. https://journalce.powerpak.com/ce/the-fda-accelerated-drug-approval#:~:text=These%20approaches%20include%20priority%20review%2C%20a%20process%20that,1%20This%20article%20will%20discuss%20the%20AA%20program
[15]
Shetty, Y.C. and Marathe, P.A. (2019) Accelerating Pharmaceutical Development through the Fast Track, Breakthrough Therapy, and Priority Review Designations. American Journal of Therapeutics, 26, e344-e352.
[16]
Johnson, J. and Stevenson, R. (2021) Enhancing IND Approval Processes through Strategic CMC Practices. Journal of Pharmaceutical Innovation, 16, 223-237. https://doi.org/10.1007/s12247-021-09509-x
[17]
ICON plc (2023) CMC in Drug Development and Life Cycle Management. https://www.iconplc.com
[18]
Hotha, K.K. (2023) Unleashing the Power of Innovation in CDMOs through Customer-Centricity and Culture of Service. American Journal of Industrial and Business Management, 13, 234-246. https://doi.org/10.4236/ajibm.2023.134016
[19]
Johnson, L. and Lee, H. (2020) Comprehensive Analytical Strategies in Drug Development. American Journal of Pharmaceutical Education, 84, 758-769.
[20]
Green, M.K. and Brown, L.T. (2022) Rapid Market Entry: Streamlined Development in the Pharmaceutical Industry. Drug Development and Industrial Pharmacy, 48, 320-330.
[21]
Davis, S. and Thompson, R. (2021) Enhancing Pharmaceutical Development through Customized Solutions. Journal of Commercial Biotechnology, 27, 34-45.
[22]
Evans, W.G. and Patel, A. (2019) Strategic Approaches to Early-Market Advantages in Biopharma. Biotechnology Advances, 37, Article ID: 107384.
[23]
Kim, Y. and Zhao, X. (2020) Expanding Market Base through Comprehensive Biopharma Strategies. Journal of Business Venturing, 35, Article ID: 105982.
[24]
European Medicines Agency (2024) ICH Q14 Analytical Procedure Development—Scientific Guideline. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q14-guideline-analytical-procedure-development-step-5_en.pdf
[25]
European Medicines Agency (2024) ICH Q2(R2) Validation of Analytical Procedures—Scientific Guideline. https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline
[26]
U.S. Food and Drug Administration (2000) Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products
[27]
Hotha, K.K., Reddy, S.P.K., Raju, V.K. and Ravindranath, L.K. (2013) Forced Degradation Studies: Practical Approach—Overview of Regulatory Guidance and Literature for the Drug Products and Drug Substances. International Research Journal of Pharmacy, 4, 78-85. https://doi.org/10.7897/2230-8407.04517
[28]
Hotha, K.K. (2023) Transforming Molecules into Medicines: Role of CDMOS in Phase-Appropriate Technology Transfers in Advancing Pharmaceutical Innovation. Advances in Chemical Engineering and Science, 13, 203-223. https://doi.org/10.4236/aces.2023.133015
